| Name | Title | Contact Details |
|---|---|---|
Amy Baldwin |
Vice President Human Resources Cardiology | Profile |
Dennis Cheng |
Vice President Cardiac Diagnostics Marketing | Profile |
Lindsay Fish |
Director, Endoscopy Finance | Profile |
Anthony Tassoni |
Principal Process Development/R&D Engineer | Profile |
Mark Wright |
Director of Research and Development | Profile |
Specialty Medical Equipment is a Norwood, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Healthy Environment Innovations is a Dover, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Luminex Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.
Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.